Literature DB >> 8406158

Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon.

T E Adrian1, G H Ballantyne, W E Longo, A J Bilchik, S Graham, M D Basson, R P Tierney, I M Modlin.   

Abstract

Peptide YY (PYY) and enteroglucagon are hormonal peptides found in endocrine cells of the distal intestinal mucosa. Although it is known that plasma concentrations of both peptides increase in response to feeding, the mechanism by which ingested food causes release of colonic hormones is not understood. The release of PYY and enteroglucagon was measured in response to intraluminal stimuli in 176 patients having investigative colonoscopy. Introduction of air, saline (isotonic and hypertonic), glucose (isotonic and hypertonic), oleic acid (without bile salts), and casein hydrolysate all failed to release PYY but glucose caused a small but significant increase in enteroglucagon concentrations. In contrast with the lack of effect of nutrients, infusion of deoxycholic acid produced a rapid and marked dose responsive increase in plasma PYY concentrations when introduced into the sigmoid colon. PYY release was statistically significant at doses between 3.3 mM to 30 mM; for example 10 mM deoxycholate caused a sixfold increase in plasma PYY concentrations. Infusion of 10 mM deoxycholate into the transverse colon or caecum produced an increase of PYY that was similar to the responses in the sigmoid colon. There was also a significant release of enteroglucagon in response to infusion of this bile salt into the sigmoid colon at doses between 3.3 mM and 30 mM. The enteroglucagon response to 10 mM deoxycholate was similar in all three colonic regions. When oleic acid was added to deoxycholate as an emulsion, the release of PYY and enteroglucagon was similar to that seen with the bile salt alone. These findings suggest that bile salts may play an important part in the control of colonic endocrine function and may explain the increased circulating concentrations of colonic regulatory peptides that are seen in malabsorption states and after small bowel resection in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8406158      PMCID: PMC1375458          DOI: 10.1136/gut.34.9.1219

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  27 in total

1.  Enteroglucagon release in the dumping syndrome.

Authors:  S R Bloom; C M Royston; J P Thomson
Journal:  Lancet       Date:  1972-10-14       Impact factor: 79.321

2.  Effect of infusion of nutrient solutions into the ileum on gastrointestinal transit and plasma levels of neurotensin and enteroglucagon.

Authors:  N W Read; A McFarlane; R I Kinsman; T E Bates; N W Blackhall; G B Farrar; J C Hall; G Moss; A P Morris; B O'Neill
Journal:  Gastroenterology       Date:  1984-02       Impact factor: 22.682

3.  Immunofluorescent localization of secretin and enteroglucagon in human intestinal mucosa.

Authors:  J M Polak; I Coulling; S Bloom; A G Pearse
Journal:  Scand J Gastroenterol       Date:  1971       Impact factor: 2.423

4.  Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem.

Authors:  P K Lund; R H Goodman; P C Dee; J F Habener
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

5.  Peptide YY (PYY) immunoreactivity is co-stored with glucagon-related immunoreactants in endocrine cells of the gut and pancreas.

Authors:  A Ali-Rachedi; I M Varndell; T E Adrian; D A Gapp; S Van Noorden; S R Bloom; J M Polak
Journal:  Histochemistry       Date:  1984

6.  Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility.

Authors:  J M Lundberg; K Tatemoto; L Terenius; P M Hellström; V Mutt; T Hökfelt; B Hamberger
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

7.  Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract.

Authors:  M A Ghatei; L O Uttenthal; N D Christofides; M G Bryant; S R Bloom
Journal:  J Clin Endocrinol Metab       Date:  1983-09       Impact factor: 5.958

8.  Inhibition of interdigestive contractile activity in the stomach by peptide YY in Heidenhain pouch dogs.

Authors:  T Suzuki; M Nakaya; Z Itoh; K Tatemoto; V Mutt
Journal:  Gastroenterology       Date:  1983-07       Impact factor: 22.682

9.  Immunocytochemical identification of polypeptide YY (PYY) cells in the human gastrointestinal tract.

Authors:  M El-Salhy; L Grimelius; E Wilander; B Ryberg; L Terenius; J M Lundberg; K Tatemoto
Journal:  Histochemistry       Date:  1983

10.  Evidence for a humoral mechanism after small intestinal resection. Exclusion of gastrin but not enteroglucagon.

Authors:  G R Sagor; M A Ghatei; M Y Al-Mukhtar; N A Wright; S R Bloom
Journal:  Gastroenterology       Date:  1983-05       Impact factor: 22.682

View more
  28 in total

1.  Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.

Authors:  Emilie Bahne; Emily W L Sun; Richard L Young; Morten Hansen; David P Sonne; Jakob S Hansen; Ulrich Rohde; Alice P Liou; Margaret L Jackson; Dayan de Fontgalland; Philippa Rabbitt; Paul Hollington; Luigi Sposato; Steven Due; David A Wattchow; Jens F Rehfeld; Jens J Holst; Damien J Keating; Tina Vilsbøll; Filip K Knop
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?

Authors:  Gaurav Chikara; Pramod Kumar Sharma; Pradeep Dwivedi; Jaykaran Charan; Sneha Ambwani; Surjit Singh
Journal:  Indian J Clin Biochem       Date:  2017-06-08

Review 3.  Classification and functions of enteroendocrine cells of the lower gastrointestinal tract.

Authors:  Ashok R Gunawardene; Bernard M Corfe; Carolyn A Staton
Journal:  Int J Exp Pathol       Date:  2011-04-25       Impact factor: 1.925

4.  Basal and fat-stimulated plasma peptide YY levels in celiac disease.

Authors:  P J Wahab; W P Hopman; J B Jansen
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

Review 5.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

6.  Ileal effect on blood glucose, HbA1c, and GLP-1 in Goto-Kakizaki rats.

Authors:  Henry Buchwald; Hector J Menchaca; Van N Michalek; Nestor T Bertin
Journal:  Obes Surg       Date:  2014-11       Impact factor: 4.129

7.  Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat.

Authors:  Bethany P Cummings; April D Strader; Kimber L Stanhope; James L Graham; Jennifer Lee; Helen E Raybould; Denis G Baskin; Peter J Havel
Journal:  Gastroenterology       Date:  2010-03-10       Impact factor: 22.682

8.  Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release.

Authors:  C Ullmer; R Alvarez Sanchez; U Sprecher; S Raab; P Mattei; H Dehmlow; S Sewing; A Iglesias; J Beauchamp; K Conde-Knape
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

9.  Peptide YY release after intraduodenal, intraileal, and intracolonic administration of nutrients in rats.

Authors:  X Fu-Cheng; Y Anini; J Chariot; T Voisin; J P Galmiche; C Rozé
Journal:  Pflugers Arch       Date:  1995-11       Impact factor: 3.657

10.  Examining acute and chronic effects of short- and long-chain fatty acids on peptide YY (PYY) gene expression, cellular storage and secretion in STC-1 cells.

Authors:  Katharine V Hand; Christine M Bruen; Fiona O'Halloran; Harsh Panwar; Danielle Calderwood; Linda Giblin; Brian D Green
Journal:  Eur J Nutr       Date:  2012-08-28       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.